Menu
Peptide Database
Results
No peptides found
Featured

Use search to browse all 100+ peptides

KPV

Lys-Pro-Val, α-MSH (11-13)

Quick Stats
Studies 104
Trials 57
1981 pubmed

Theoretical and practical considerations in the application of killed poliovirus vaccine for the control of paralytic poliomyelitis.

Salk. J J; van Wezel. A L AL; Stoeckel. P P; van Steenis. G G; Schlumberger. M M; Meyran. M M; Rey. J L JL; Lapinleimu. K K; Böttiger. M M; Cohen. H H

Key Findings

  • Effective KPV requires specific amounts of D‑antigen units: 40 for type I, 8 for type II, and 32 for type III.
  • A single or two‑dose regimen could be sufficient if the vaccine contains enough antigen to induce antibodies and immune memory.
  • The manufacturing method used by the Dutch National Institute of Public Health is recommended as a reference standard.

Practical Outcomes

  • For most biohackers and self‑experimenters, this information offers little direct value. It does not provide actionable protocols for longevity, metabolic health, or performance enhancement, and the vaccine is not something individuals can safely produce or use outside of regulated medical settings.

Summary

The paper explains how a killed poliovirus vaccine (KPV) can be made and standardized, focusing on the amount of viral antigen needed for each of the three poliovirus types to trigger a strong immune response.

Abstract

This paper contains a summary of the principles upon which the preparation and use of killed poliovirus vaccine (KPV) are based, as well as a summary of earlier and more recent work suggesting the feasibility of formulating a KPV preparation that would be fully and durably effective in a one- or two-dose regimen. The essential factor in the preparation of such a vaccine is the inclusion of a sufficient mass of the immunizing antigen, for each of the three antigenic types of poliovirus, to induce the formation of humoral antibody and/or immunologic memory after the first dose. The results of a series of studies carried out in West African and Scandinavian countries are summarized, which suggest that such a vaccine should contain 40, 8, and 32 D-antigen units for types I, II and III, respectively. If the D-antigen unit measurement is to be used as a guide to KPV standardization, the details of the method of manufacture are important; in this regard, the method of vaccine preparation used at the Rijks Instituut voor de Volksgezondheid should serve as a reference standard for the preparation of vaccines expected to produce the effects described.

Study Information

Provider

pubmed

Year

1981